FM6 860
689
Adjuvant and Salvage Radiotherapy after Radical Prostatectomy in Prostate Cancer PatientsG. Gandaglia, A. Briganti, N. Clarke, R.J. Karnes, M. Graefen, P. Ost, A.L. Zietman, M. Roach III
Adjuvant radiotherapy reduces the risk of recurrence after radical prostatectomy in
patients with aggressive disease characteristics. However, it may be associated with
a higher risk of Grade 2 and 3 genitourinary effects at long-term follow-up.
Observation followed by salvage radiotherapy administered at the first sign of
recurrence might be associated with durable cancer control in selected patients but
may compromise cure in others.
710
Post-prostatectomy Radiotherapy: Does “Salvage” Really Equal “Adjuvant”?A. Bossi, C. Cozzarini
712
Cost of New Technologies in Prostate Cancer Treatment: Systematic Review of Costs and Cost Effectiveness of Robotic-assisted Laparoscopic Prostatectomy, Intensity-modulated Radiotherapy, and Proton Beam TherapyF.R. Schroeck, B.L. Jacobs, S.B. Bhayani, P.L. Nguyen, D. Penson, J. Hu
Robot-assisted radical prostatectomy, intensity-modulated radiotherapy, and
proton beam therapy for prostate cancer cost more than their traditional
counterparts. Uncertainty surrounding improvements in outcomes limits our ability
to estimate cost effectiveness. If the new technologies can consistently achieve
better outcomes, then they may be cost effective.
736
Value of Prostate Cancer Care: New Information on New Therapies Suggest Less is MoreT.J. Wilt, P. Dahm
738
Brachytherapy Boost Utilization and Survival in Unfavorable-risk Prostate CancerS.B. Johnson, N.H. Lester-Coll, J.R. Kelly, B.H. Kann, J.B. Yu, S.K. Nath
Low-dose rate brachytherapy boost, despite a decline in utilization between 2004
and 2012, was independently associated with better overall survival when
compared to dose-escalated radiation therapy alone for men with unfavorable-risk
prostate cancer.
745
Optimal Radiotherapy for Unfavorable-risk Prostate CancerJ. Crook
747
Genetic Variants Related to Longer Telomere Length are Associated with Increased Risk of Renal Cell CarcinomaM.J. Machiela, J.N. Hofmann, R. Carreras-Torres, K.M. Brown, M. Johansson, Z. Wang, M. Foll, P. Li,
N. Rothman, S.A. Savage, V. Gaborieau, J.D. McKay, Y. Ye, M. Henrion, F. Bruinsma, S. Jordan, G. Severi,
K. Hveem, L.J. Vatten, T. Fletcher, K. Koppova, S.C. Larsson, A. Wolk, R.E. Banks, P.J. Selby, D.F. Easton,
P. Pharoah, G. Andreotti, L.E.B. Freeman, S. Koutros, D. Albanes, S. Mannisto, S. Weinstein, P.E. Clark,
T.E. Edwards, L. Lipworth, S.M. Gapstur, V.L. Stevens, H. Carol, M.L. Freedman, M.M. Pomerantz,
E. Cho, P. Kraft, M.A. Preston, K.M. Wilson, J.M. Gaziano, H.S. Sesso, A. Black, N.D. Freedman,
W.-Y. Huang, J.G. Anema, R.J. Kahnoski, B.R. Lane, S.L. Noyes, D. Petillo, L.M. Colli, J.N. Sampson,
C. Besse, H. Blanche, A. Boland, L. Burdette, E. Prokhortchouk, K.G. Skryabin, M. Yeager, M. Mijuskovic,
M. Ognjanovic, L. Foretova, I. Holcatova, V. Janout, D. Mates, A. Mukeriya, S. Rascu, D. Zaridze,
V. Bencko, C. Cybulski, E. Fabianova, V. Jinga, J. Lissowska, J. Lubinski, M. Navratilova, P. Rudnai,
N. Szeszenia-Dabrowska, S. Benhamou, G. Cancel-Tassin, O. Cussenot, H.B. Bueno-de-Mesquita,
F. Canzian, E.J. Duell, B. Ljungberg, R.T. Sitaram, U. Peters, E. White, G.L. Anderson, L. Johnson, J. Luo,
J. Buring, I-M. Lee, W.-H. Chow, L.E. Moore, C. Wood, T. Eisen, J. Larkin, T.K. Choueiri, G.M. Lathrop,
B.T. Teh, J.-F. Deleuze, X. Wu, R.S. Houlston, P. Brennan, S.J. Chanock, G. Scelo, M.P. Purdue
This large Mendelian randomization study utilizes a risk score of telomere length
associated genetic variants to demonstrate a strong association between longer
predicted leukocyte telomere length and increased risk of developing common
subtypes of renal cell carcinoma.
755
Longer Telomere Length and Renal Cell CarcinomaJ. Casuscelli, A.A. Hakimi
e u r o p e a n u r o l o g y , vo l . 7 2 , n o . 5 , No v emb e r 2 0 1 7
Kidney Cancer